PortalPublikationenWhat is the outcome in patients with acute leukaemia who sur...

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Standard

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? / Ringdén, O; Labopin, M; Sadeghi, B; Mailhol, A; Beelen, D; Fløisand, Y; Ghavamzadeh, A; Finke, J; Ehninger, G; Volin, L; Socié, G; Kröger, N; Stuhler, G; Ganser, A; Schmid, C; Giebel, S; Mohty, M; Nagler, A.

in: J INTERN MED, Jahrgang 283, Nr. 2, 02.2018, S. 166-177.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ringdén, O, Labopin, M, Sadeghi, B, Mailhol, A, Beelen, D, Fløisand, Y, Ghavamzadeh, A, Finke, J, Ehninger, G, Volin, L, Socié, G, Kröger, N, Stuhler, G, Ganser, A, Schmid, C, Giebel, S, Mohty, M & Nagler, A 2018, 'What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?', J INTERN MED, Jg. 283, Nr. 2, S. 166-177. https://doi.org/10.1111/joim.12695

APA

Ringdén, O., Labopin, M., Sadeghi, B., Mailhol, A., Beelen, D., Fløisand, Y., Ghavamzadeh, A., Finke, J., Ehninger, G., Volin, L., Socié, G., Kröger, N., Stuhler, G., Ganser, A., Schmid, C., Giebel, S., Mohty, M., & Nagler, A. (2018). What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J INTERN MED, 283(2), 166-177. https://doi.org/10.1111/joim.12695

Vancouver

Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y et al. What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J INTERN MED. 2018 Feb;283(2):166-177. https://doi.org/10.1111/joim.12695

Bibtex

@article{acfa1f91a20f41308f7b11097447e478,
title = "What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?",
abstract = "BACKGROUND: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD.OBJECTIVES: We wanted to analyze the long-term outcome in patients who survive severe aGVHD.METHODS: This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002-2014. Patients alive after severe aGVHD (n = 1738) were compared to controls.RESULTS: Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10-5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10-5 ). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD.CONCLUSIONS: HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD.",
keywords = "Journal Article",
author = "O Ringd{\'e}n and M Labopin and B Sadeghi and A Mailhol and D Beelen and Y Fl{\o}isand and A Ghavamzadeh and J Finke and G Ehninger and L Volin and G Soci{\'e} and N Kr{\"o}ger and G Stuhler and A Ganser and C Schmid and S Giebel and M Mohty and A Nagler",
note = "{\textcopyright} 2017 The Association for the Publication of the Journal of Internal Medicine.",
year = "2018",
month = feb,
doi = "10.1111/joim.12695",
language = "English",
volume = "283",
pages = "166--177",
journal = "J INTERN MED",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

AU - Ringdén, O

AU - Labopin, M

AU - Sadeghi, B

AU - Mailhol, A

AU - Beelen, D

AU - Fløisand, Y

AU - Ghavamzadeh, A

AU - Finke, J

AU - Ehninger, G

AU - Volin, L

AU - Socié, G

AU - Kröger, N

AU - Stuhler, G

AU - Ganser, A

AU - Schmid, C

AU - Giebel, S

AU - Mohty, M

AU - Nagler, A

N1 - © 2017 The Association for the Publication of the Journal of Internal Medicine.

PY - 2018/2

Y1 - 2018/2

N2 - BACKGROUND: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD.OBJECTIVES: We wanted to analyze the long-term outcome in patients who survive severe aGVHD.METHODS: This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002-2014. Patients alive after severe aGVHD (n = 1738) were compared to controls.RESULTS: Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10-5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10-5 ). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD.CONCLUSIONS: HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD.

AB - BACKGROUND: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD.OBJECTIVES: We wanted to analyze the long-term outcome in patients who survive severe aGVHD.METHODS: This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002-2014. Patients alive after severe aGVHD (n = 1738) were compared to controls.RESULTS: Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10-5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10-5 ). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD.CONCLUSIONS: HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD.

KW - Journal Article

U2 - 10.1111/joim.12695

DO - 10.1111/joim.12695

M3 - SCORING: Journal article

C2 - 29027756

VL - 283

SP - 166

EP - 177

JO - J INTERN MED

JF - J INTERN MED

SN - 0954-6820

IS - 2

ER -